224161-37-9

Basic information

• Product Name: 6-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE
• Synonyms: 6-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE;Isoquinoline, 6-fluoro-1,2,3,4-tetrahydro- (9CI);Isoquinoline, 6-fluoro-1,2,3,4-tetrahydro-
• CAS NO: 224161-37-9
• Molecular Formula: C₉H₁₀FN
• Molecular Weight: 151.18
• Product Categories: HALIDE
• Mol File: 224161-37-9.mol

Chemical Properties

• Boiling Point: 227.55 °C at 760 mmHg
• Flash Point: 91.419 °C
• Appearance: /
• Density: 1.108 g/cm³
• CAS DataBase Reference: 6-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE(224161-37-9)
• EPA Substance Registry System: 6-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE(224161-37-9)

Safety Data

• Hazardous Substances Data: 224161-37-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its unique chemical structure and properties contribute to the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry:
6-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE is utilized in medicinal chemistry for its potential applications in drug development. Its unique structure and properties allow for the creation of novel compounds with potential therapeutic effects.
Used in Neurochemistry Research:
6-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE may have biological activity, making it a valuable research tool in the study of neurochemistry. Its unique properties can be used to investigate the interactions between compounds and neurotransmitter systems, contributing to a better understanding of neurological processes and the development of treatments for neurological disorders.
Used in Pharmacology Research:
6-FLUORO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE can be employed as a research tool in pharmacology to study the effects of various compounds on biological systems. Its unique structure and properties can provide insights into drug interactions, mechanisms of action, and potential therapeutic applications.

InChI:InChI=1/C9H10FN/c10-9-2-1-8-6-11-4-3-7(8)5-9/h1-2,5,11H,3-4,6H2

Upstream product

• 224161-38-0 6-fluoro-3,4-dihydroisoquinoline 
• 404-70-6 2-(3-Fluorophenyl)ethylamine 
• 700-84-5 5-fluoro-1-indanone 
• 214045-84-8 6-fluoro-3,4-dihydro-2H-isoquinolin-1-one 

Downstream Products

• 1236265-32-9 N-ethyl-4-((4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-N-m-tolylbenzamide 
• 224161-38-0 6-fluoro-3,4-dihydroisoquinoline 
• 1009344-24-4 N-(2-chloro-4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-6-(trifluoromethyl)phenyl)-3,3-dimethylbutanamide 

Relevant articles and documents

Intramolecular Reductive Cyclization of o-Nitroarenes via Biradical Recombination

A visible-light-induced/thiourea-mediated intramolecular cyclization of o-nitroarenes under mild conditions is realized for the first time, which provides an efficient and environmentally friendly way to access pharmaceutical relevant quinazolinone derivatives. The reaction can be easily extended to gram level by using a continuous-flow setup with high efficiency. Mechanistic investigation including control experiments, transient fluorescence, UV-vis spectra, and DFT calculations suggests that the formation of active biradical intermediates via intramolecular single electron transfer (SET) is key stage in the catalytic cycle.

Metal-Free Synthesis of Polycyclic Quinazolinones Enabled by a (NH4)2S2O8-Promoted Intramolecular Oxidative Cyclization

An efficient metal-free, (NH4)2S2O8 mediated intramolecular oxidative cyclization for the construction of polycyclic heterocycles was disclosed. A series of polycyclic quinazolinone derivatives with good functional group tolerance were obtained in high yields. The natural products tryptanthrin and rutaecarpine, as well as their derivatives, were easily synthesized by this strategy. A preliminary mechanism study suggested the carbon-centered radical was involved in the catalytic cycle.

Light-Driven Intramolecular C?N Cross-Coupling via a Long-Lived Photoactive Photoisomer Complex

Reported herein is a visible-light-driven intramolecular C?N cross-coupling reaction under mild reaction conditions (metal- and photocatalyst-free, at room temperature) via a long-lived photoactive photoisomer complex. This strategy was used to rapidly prepare the N-substituted polycyclic quinazolinone derivatives with a broad substrate scope (>50 examples) and further exploited to synthesize the natural products tryptanthrin, rutaecarpine, and their analogues. The success of gram-scale synthesis and solar-driven transformation, as well as promising tumor-suppressing biological activity, proves the potential of this strategy for practical applications. Mechanistic investigations, including control experiments, DFT calculations, UV-vis spectroscopy, EPR, and X-ray single-crystal structure of the key intermediate, provides insight into the mechanism.

TRIAZOLOPHTHALAZINE COMPOUNDS, USE AS ANTI-HUMAN IMMUNODEFICIENCY VIRUS INHIBITORS OF HIV VIF-DEPENDENT DEGRADATION OF APOBEC3

The present disclosure is concerned with triazolophthalazine compounds that are capable of inhibiting infection by the Human Immunodeficiency Virus (HIV) by inhibiting HIV Vif-dependent degradation of the APOBEC3 innate immune system. The present disclosu

Synthesis and evaluation of tetrahydroisoquinoline-benzimidazole hybrids as multifunctional agents for the treatment of Alzheimer's disease

A novel series of tetrahydroisoquinoline-benzimidazole hybrids have been designed and synthesized as multifunctional agents against Alzheimer's disease (AD). These compounds were evaluated for their inhibition of neuroinflammation and human β-secretase (hBACE1), and neuroprotective activity. Among them, compound BD3 possessed significant anti-neuroinflammatory activity (IC50 = 5.07 μM against nitric oxide production) through inhibiting the expression and secretion of proinflammatory cytokines in BV2 cells. Compound BD3 also exhibited moderate hBACE1 inhibitory activity (65.7% inhibition at 20 μM) and potent neuroprotective effect by increasing GSH level and reducing ROS production (91.8% cell viability at 5 μM). Parallel artificial membrane permeation assay demonstrated that BD3 could cross the blood-brain barrier (BBB). Thus, this study demonstrates that the compounds with tetrahydroisoquinoline-benzimidazole scaffold are potential anti-AD agents, and they are worth for the further development.

A multi-functional the anti-ahl tribulus sea is silent disease of the benzimidazole derivatives and its preparation method and application

The invention provides a multi-functional anti-the erzierzi sea is silent disease of benzimidazole derivative and its preparation method and application. Said styrene and imidazole derivatives having a structure of formula (I) is shown; Wherein formula (I) R in1 Is H, C1 - C5 alkyl, C1 - C5 alkoxy, halogen base, hydroxy or amino, X is C or N atom. The invention is based on the fragment assembly of the lead compound discovery method, through the tetrahydroisoquinoline and benzimidazole two fragment assembly, design is a new skeleton molecule, and synthesizing a series of benzimidazole derivatives. The present invention provides a benzimidazole derivative with antineuritic activity at the same time, BACE1 inhibitory activity and cell protective activity, and can penetrate the blood-brain barrier; at the same time the benzimidazole derivatives for the preparation of simple, low cost, stable structure, convenient for storage, can be used as a treating [...] of one kind of precursor compound.

NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The present invention provides novel compounds having the general formula (I): wherein R1, R 2, R 3, U, V, W, X and Y are as described herein, compositions including the compounds and methods of using the compounds.

ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF

The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X1, X2, X3, X4, X5, X6, X7 and X8 are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.

Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators

This invention provides a compound of formula IA where X═O or S; Y is O or S; q=1 or 0; and other substituents are defined herein. Such compounds can affect the opening of, or otherwise modulate, voltage-gated potassium channels. They are potentially usef